European Companies Search Engine
EU funding (€20.1M): Optimizing a deployable high efficacy malaria vaccine Hor15 Dec 2016 EU Research and Innovation programme "Horizon"
Overview
Text
Optimizing a deployable high efficacy malaria vaccine
A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates. Our approach tackles the toughest problems in malaria vaccine design: choice of the best antigens, attaining high immunogenicity, avoiding polymorphic antigens and increasing the durability of vaccine immunogenicity and efficacy. We take advantage of several recent advances in vaccinology and adopt some very new technologies: sequencing malaria peptides eluted from the HLA molecules, parasites expressing multiple transgenes, multi-antigen virus-like particles constructed with new bonding technologies, delayed release microcapsules, and liver-targeted immunisation with vaccine vectors. We enhance our chances of success by using a multi-stage multi-antigen approach, by optimising the magnitude and durability of well-characterised immune responses to key antigens, and using stringent infectious challenges and functional assays as established criteria for progression at each stage. The consortium comprises many of the foremost researchers in this field in Europe with leading groups in the USA, Australia and Africa. We link to EDCTP programmes and harmonise our timeline to fit with the recent roadmaps for malaria vaccine development. We include a major pharma partner and several excellent European biotech companies helping enhance Europe’s leading position in the commercial development of vaccines. This ambitious and exciting programme should have a high chance of success in tackling the major global health problem posed by malaria.
Funded Companies:
| Company name | Funding amount |
| Academisch Ziekenhuis Leiden | €1,179,726 |
| Expres2ION Biotechnologies ApS | €445,056 |
| Genome Research Ltd. | €250,000 |
| Imaxio SA | €5,158.05 |
| Institut de Recherche Pour le Developpement | €183,775 |
| €0.00 | |
| Janssen Vaccines & Prevention B.V. | €25,000 |
| €25,000 | |
| Novavax AB | €150,000 |
| Osivax SAS | €19,841.95 |
| €25,000 | |
| Sorbonne Universite | €437,500 |
| Statens Serum Institut | €1,965,000 |
| Stichting Radboud Universitair Medisch Centrum | €3,274,888 |
| €0.00 | |
| The Chancellor, Masters and Scholars of the University of Oxford | €12.1M |
| UNIVERSITE DE LAUSANNE | €0.00 |
| United Kingdom Research and Innovation | €0.00 |
| VACCINE FORMULATION INSTITUTE(CH)Ltd. | €0.00 |
Source: https://cordis.europa.eu/project/id/733273
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Academisch Ziekenhuis Leiden - EU funding (€20.1M): Optimizing a deployable high efficacy malaria vaccine"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
